The fact that TNF inhibitors, such as antibodies or soluble TNFR proteins have been highly successful for treatment of several immune diseases, including rheumatoid arthritis [9], [10], led to great interest in other members of the superfamily as possible alternate or additional therapeutic targets for inflammatory and autoimmune disease. This evidence concerns the gene TNFRSF1A and rheumatoid arthritis.